Biosynthetic processing and quaternary interactions of proprotein convertase SPC4 (PACE4)  by Nagahama, Masami et al.
Biosynthetic processing and quaternary interactions of proprotein
convertase SPC4 (PACE4)
Masami Nagahama, Takazumi Taniguchi, Emi Hashimoto, Akiyoshi Imamaki, Kenji Mori,
Akihiko Tsuji, Yoshiko Matsuda*
Department of Biological Science and Technology, Faculty of Engineering, The University of Tokushima, 2-1 Minamijosanjima,
Tokushima 770-8506, Japan
Received 12 June 1998; revised version received 27 July 1998
Abstract SPC4 (PACE4), a member of the eukaryotic family
of subtilisin-like proprotein convertases, is synthesized as a
proenzyme (proSPC4) which undergoes proteolytic removal of
N-terminal propeptide during transit through the secretory
pathway. As this propeptide processing seems to be a key event
in the functional expression of SPC4, we have investigated its
mechanism and the intracellular site where it occurs. In
transfected fibroblast cells, the 110-kDa proSPC4 undergoes
slow cleavage to generate a 103-kDa mature enzyme in the
endoplasmic reticulum (ER). Site-directed mutagenesis studies
demonstrate that the proteolytic activation of SPC4 occurs
mainly through a unimolecular autocatalytic process and
propeptide cleavage is a prerequisite for its export from the
ER. Sedimentation velocity and chemical cross-linking analysis
demonstrate that the precursor protein in the cells exists as both
a monomer and a dimer-sized complex whereas mature SPC4
exists only as a monomer. These results suggest that the cleavage
of the N-terminal propeptide of SPC4 plays a regulatory role in
its activation and secretion through the change in its oligomeric
state.
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1. Introduction
SPC4 (also called PACE4) is a member of the subtilisin-like
proprotein convertase (SPC) family which is responsible for
proteolytic processing of many bioactive peptide precursors at
paired or multiple basic sites. To date, seven members of this
family have been identi¢ed: SPC1/furin, SPC2/PC2, SPC3/
PC1/PC3, SPC4/PACE4, SPC5/PC4, SPC6/PC5/PC6 and
SPC7/PC7/PC8/LPC (for reviews see [1^3]). All members of
the SPC family share certain structural features: an N-termi-
nal signal peptide, followed by a propeptide region, a subtili-
sin-like catalytic domain, a conserved domain of unknown
function named the HomoB domain or P-domain, and a di-
vergent C-terminal tail. These convertases have overlapping
but not identical substrate speci¢city, and they are di¡erently
distributed in tissues and show maximal activity in di¡erent
cellular compartments. Identifying the physiological substrate
of these convertases is vital if one is to understand the regu-
lation of biosynthesis of bioactive peptides and proteins such
as neuropeptides, peptide hormones, growth factors, receptors
and plasma proteins.
SPC4 is expressed in a wide range of tissues or cells with
relatively high expression levels in particular tissues such as
pituitary and nervous systems. For human SPC4, eight di¡er-
ent isoforms arising from alternative gene splicing events have
so far been reported [4^7]: they are SPC4A-I, SPC4A-II,
SPC4B, SPC4C, SPC4CS, SPC4D, SPC4E-I, and SPC4E-II.
Previous studies demonstrated that these isoforms show dis-
tinct patterns of tissue distribution [8^10], and di¡erent prop-
erties of secretion [7]. Evidence that implicates SPC4 in devel-
opment and pathogenesis, such as limb development [11],
establishment of the olfactory system [10], and tumor progres-
sion [12], is accumulating. Recently, we reported the gene
structure of human SPC4 [13]. The sequence of its 5P-£anking
region revealed characteristic potential regulatory elements
such as an E-box cluster, suggesting the dynamic regulation
of SPC4 expression during development.
Studies have been performed to demonstrate the processing
activity of SPC4 against several precursor proteins using het-
erologous expression systems in cultured cell lines. However,
in most cases, SPC4 showed no or extremely low levels of
activity compared to other convertases, and a promising can-
didate for the physiological substrate has not been identi¢ed.
One reason for this weak activity of SPC4 could be the in-
appropriateness of the expression systems employed in the
experiments. Since SPC4 is synthesized as an inactive precur-
sor proSPC4 and then converted into the mature active pro-
tein in the cells before its secretion [7,14], the rate of the
removal of the N-terminal propeptide of SPC4 could conceiv-
ably represent a mechanism by which the cell could control
the e⁄ciency of substrate processing. Previous studies did not
give su⁄cient consideration to the maturation e⁄ciency of the
enzyme in the cells despite the potential importance of the
propeptide cleavage as a possible regulatory step. In this con-
text, here we have clari¢ed the mechanism of intracellular
maturation and secretion of human SPC4, which is critically
important to the understanding of the regulation of propro-
tein processing by this enzyme.
2. Materials and methods
2.1. Expression plasmids and site-directed mutagenesis
For transient expression of SPC4 in mammalian cells, human
SPC4A-I cDNA was subcloned into mammalian cell expression vector
pALTER-MAX (Promega). Site-directed mutagenesis was performed
on this plasmid and the following mutants were generated using Al-
tered sites II mammalian mutagenesis system (Promega); RQ149
(Arg149CGln), KR144 (Lys144CArg), DN205 (Asp205CAsn),
SA420 (Ser420CAla) and SPC4v680 (introduction of a stop codon
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3P (SA420), and 5P-GAAGATTACACATAGCAATCCACCC-3P
(SPC4v680), with the mutated nucleotides underlined. The expression
plasmid for mouse Ren-2 prorenin mutant, M2Rÿ6Rÿ4, was kindly
provided by K. Nakayama and K. Murakami (University of Tsukuba,
Japan) [15].
2.2. Preparation of antibodies
To generate a polyclonal antibody to SPC4, the HomoB region of
SPC4 (456^688) with an amino-terminal hexa-histidine was prepared
by inserting the appropriate region of human SPC4 cDNA into pQE-
30 vector (Qiagen). After expression in Escherichia coli strain XL1-
Blue cells, the protein was puri¢ed from inclusion bodies under dena-
turing conditions by a⁄nity chromatography using Ni-nitrilotriacetic
acid agarose (Qiagen) as described by the manufacturer. The protein
was eluted in 8 M urea, 0.1 M NaH2PO4 and 0.01 M Tris (pH 4.5),
and then injected into rabbits for immunization.
For the production of monoclonal antibodies speci¢c for SPC4A,
BALB/c mice were immunized by intraperitoneal injections of peptide
TGFTQLGTSCITNHTCSNAD (corresponding to amino acids 920^
939 of SPC4A-I) conjugated with keyhole limpet hemocyanin. The
isolated spleen cells were fused with SP2/0 myeloma cells. Colonies
were selected by immunoblotting and immunoprecipitation against
SPC4A-I overexpressed in COS-1 cells. The tissue culture superna-
tants from the clone A121G09 cell line were used for the experiments.
2.3. Cell culture and transfection
HEK293 cells and COS-1 cells were grown in Dulbecco’s modi¢ed
Eagle’s medium containing 10% FBS. HEK293 cells were transfected
by the calcium phosphate method using the CellPhect transfection kit
(Pharmacia) as described by the manufacturer and subjected to radio-
labeling at 40 h post-transfection. Transfection of COS-1 cells was
performed by the DEAE-dextran method as described previously [7].
2.4. Radiolabeling and immunoprecipitation
Transfected cells were washed with PBS, and then switched for 30
min to a methionine- and cysteine-free medium supplemented with
10% dialyzed FBS. Subsequently, cells were labeled for 6 h with
[35S]methionine/cysteine (100 WCi/ml) (s 1000 Ci/mmol, Dupont-
New England Nuclear). In experiments performed with brefeldin A
(Sigma), the cells were preincubated for 1 h, and then labeled for 6 h
and the drug was used throughout the preincubation and labeling
period at a ¢nal concentration of 5 Wg/ml. At the end of the incuba-
tion period, the media were removed and cells were disrupted in lysis
bu¡er (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Triton X-100,
1 mM EDTA, 1 mM PMSF, 2 Wg/ml leupeptin, 2 Wg/ml aprotinin and
2 Wg/ml pepstatin A) by incubating at 4‡C for 30 min. The media and
cell lysates were precleared in two steps using normal rabbit serum
and protein A-Sepharose 4 Fast Flow (Pharmacia), and then incu-
bated with antiserum for 1 h. Immune complexes were isolated by
shaking overnight with protein A-Sepharose 4 Fast Flow and the
beads were washed twice with bu¡er 1 (10 mM Tris-HCl, pH 7.5,
150 mM NaCl, 0.5% Nonidet P-40, 1 mM EDTA), three times with
bu¡er 2 (10 mM Tris-HCl, pH 7.5, 500 mM NaCl, 0.5% Nonidet P-
40, 1 mM EDTA), three times with bu¡er 3 (10 mM Tris-HCl, pH
7.5, 150 mM NaCl, 0.5% Triton X-100, 0.5% sodium deoxycholate,
0.05% sodium dodecyl sulfate (SDS), 1 mM EDTA), and twice with
bu¡er 4 (10 mM Tris-HCl, pH 7.5, 0.1% SDS). Endoglycosidase H
(Boehringer Mannheim) and peptide N-glycosidase F (New England
Biolabs) digestions were performed overnight at 37‡C according to the
manufacturers’ instructions. The immunoprecipitation products were
resolved by SDS-polyacrylamide gel electrophoresis followed by £uo-
rography.
2.5. Sedimentation velocity analysis
Transiently transfected COS-1 cells expressing wild-type SPC4 was
metabolically labeled with [35S]methionine/cysteine in serum-free
DMEM and then solubilized in 0.5% Triton X-100, 0.2 M KCl,
50 mM Tris-HCl, pH 7.5, 1 mM EDTA, 10 Wg/ml leupeptin and
10 Wg/ml E-64. The culture medium was concentrated to 0.2 ml by
ultra¢ltration. The cell lysate and concentrated medium were applied
to the top of linear 5^20% (w/v) sucrose gradients and centrifuged for
17 h at 4‡C in a SW41 rotor at 35 000 rpm. Each 450 Wl fraction was
collected and subjected to immunoprecipitation with the polyclonal
antibody to SPC4.
2.6. Chemical cross-linking
Transiently transfected COS-1 cells expressing wild-type SPC4 or
SA420 mutant were solubilized in 1% Triton X-100, 150 mM NaCl
and 50 mM borate (pH 8.1). The serum-free cultured medium was
concentrated by ultra¢ltration and conditioned to 50 mM borate (pH
8.1). The cleared cell lysates and medium were incubated at room
temperature with 1.2 mM dimethyl suberimidate (DMS) for 3 h.
The cross-linked samples were subjected to Western blot analysis us-
ing the monoclonal antibody to SPC4A.
3. Results
3.1. Maturation of SPC4 occurs in the endoplasmic reticulum
In this study, transient expression in ¢broblast cells was
used to precisely analyze the biosynthetic processing of
SPC4 (PACE4). Expression plasmids for SPC4A-I were tran-
siently transfected into HEK293 cells. Cells were radiolabeled
for 6 h with [35S]methionine/cysteine and then the cell extracts
and conditioned medium were subjected to immunoprecipita-
tion with the anti-SPC4 antiserum. In the cell extracts, SPC4A
was detected as two bands, a major 110-kDa precursor pro-
tein and a minor 103-kDa mature protein, and the latter was
secreted into the medium as previously described [7] (Fig. 1A,
lanes 1 and 4). Since human SPC4A contains three potential
N-glycosylation sites, sensitivity to endoglycosidase digestion
was used to determine the intracellular site of the maturation
of SPC4. Immature oligosaccharide chains were found on
both the precursor and mature form of SPC4 in the cell ex-
tract: the products of peptide N-glycosidase F (PNGase F)
and endoglycosidase H digestion exhibited similar apparent
molecular masses (Fig. 1A, lanes 2 and 3). Endoglycosidase
H treatment never diminished the apparent molecular mass of
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Fig. 1. Analysis of the intracellular site for the maturation of SPC4.
A: N-Glycosylation analysis of SPC4. HEK293 cells transiently ex-
pressing SPC4A-I were biosynthetically labeled with [35S]Met/Cys
for 6 h. Samples were immunoprecipitated with anti-SPC4 antiserum
and then treated with bu¡er only (lanes C), endoglycosidase H
(lanes H) or protein N-glycosidase F (lanes F) before analysis by
SDS-PAGE. B: E¡ects of brefeldin A on the maturation and secre-
tion of SPC4. HEK293 cells transiently expressing SPC4A-I were
biosynthetically labeled with [35S]Met/Cys for 6 h in the presence or
absence of brefeldin A. Cell extracts (lanes c) or media (lanes m)
were immunoprecipitated with anti-SPC4 antiserum, followed by
resolution by SDS-PAGE. The arrowheads indicate the proSPC4
protein and the double arrowheads indicate mature SPC4 protein.
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secreted SPC4 to the same extent as did PNGase F treatment
(Fig. 1A, lanes 5 and 6), indicating the protein had acquired
endoglycosidase H-resistant oligosaccharide after the conver-
sion from proSPC4. Since the processed SPC4 protein in the
cell extract contained endoglycosidase H-sensitive oligosac-
charide, while the secreted SPC4 protein did not, the endo-
proteolytic cleavage converting proSPC4 to the mature pro-
tein must have occurred at a site before the medial Golgi.
As another approach to investigate the cellular site of SPC4
maturation, radiolabeling studies in the presence or absence of
the fungal metabolite brefeldin A were performed with
SPC4A-I transfected HEK293 cells (Fig. 1B). Brefeldin A
causes accumulation of secretory proteins in the endoplasmic
reticulum (ER) [16,17]. In the absence of brefeldin A, the
precursor proSPC4 and the processed mature SPC4 were ob-
served in the cell extract and the mature SPC4 was secreted
into the medium. In the presence of brefeldin A, the secretion
of the processed mature SPC4 was completely inhibited
although the conversion of proSPC4 occurred in the cells,
indicating that this drug e¡ectively blocked transport of pro-
teins in the secretory pathway of these cells but not proSPC4
maturation which takes place in the ER.
3.2. Proteolytic maturation is a prerequisite for SPC4 to leave
the ER
To determine whether the propeptide cleavage has in£uence
on the tra⁄cking of SPC4 in cells, SPC4s harboring a muta-
tion at their propeptide cleavage site were constructed. The
processing site of proSPC4 contains the multiple basic amino
acids Lys-Arg-Arg-Val-Lys-Arg31 which is a consensus signal
for cleavage by SPC family proteases including SPC4 itself.
Thus, the Arg residue in the P1 position of the processing site
of proSPC4A-I was replaced by Gln to generate Lys-Arg-Arg-
Val-Lys-Gln31 so that the consensus processing motif was
disrupted (RQ149). HEK293 cells expressing the wild-type
proSPC4 or the RQ149 mutant were metabolically labeled,
and their maturation and secretion were compared (Fig. 2).
Unlike the wild-type SPC4, the RQ149 mutant did not under-
go any detectable endoproteolytic cleavage as expected, nor
was secretion detectable. A Lys to Arg mutation at the P6
position to generate Arg-Arg-Arg-Val-Lys-Arg31 processing
site (KR144), which does not harm the consensus motif, did
not a¡ect the e⁄ciency of either the maturation or secretion
of SPC4. Taken together, these results show that the propep-
tide processing of SPC4 and its export from the ER are se-
quential events and the propeptide cleavage is prerequisite for
SPC4 to exit from the ER.
3.3. Intramolecular autoactivation of SPC4
To examine whether a mutant form of proSPC4 that should
not yield active enzyme could have its propeptide region
cleaved, the Asp residue in the catalytic triad of SPC4 was
mutated to Asn (DN205) or the Ser residue was mutated to
Ala (SA420). When these active site mutants were expressed in
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Fig. 4. Analysis of the oligomerization state of SPC4. A: COS-1
cells were transiently transfected with SPC4A-I. Conditioned me-
dium or detergent lysate of the cells were fractionated by sedimenta-
tion on 5^20% sucrose gradients for 17 h. Individual gradient frac-
tions were immunoprecipitated with anti-SPC4 antiserum, and then
analyzed by SDS-PAGE and £uorography. Bovine serum albumin
(V67 kDa), aldolase (V160 kDa) and catalase (V250 kDa) were
used as internal size standards. B: COS-1 cells were transiently
transfected with wild-type SPC4 or the active site mutant SA420.
Conditioned media or detergent lysates of the cells were cross-linked
with 1.2 mM of DMS. Samples were analyzed by Western blotting
using the anti-SPC4A monoclonal antibody.
Fig. 3. Processing of active site mutant of SPC4. A: HEK293 cells
transiently expressing SPC4A-I (WT) or its active site mutants
(DN205 and SA420) were biosynthetically labeled with [35S]Met/Cys
for 6 h. Cell extracts (lanes c) or media (lanes m) were immunopre-
cipitated with anti-SPC4 antiserum, followed by resolution by SDS-
PAGE. B: SPC4A-I (WT) or its active site mutant (SA420) was ex-
pressed in combination with C-terminally shortened SPC4 (v680) in
HEK293 cells, and then cells were biosynthetically labeled with
[35S]Met/Cys for 6 h. Cell extracts (lanes c) or media (lanes m) were
immunoprecipitated with anti-SPC4 antiserum, followed by resolu-
tion by SDS-PAGE.
Fig. 2. Role of the propeptide cleavage of SPC4 in secretion.
HEK293 cells transiently expressing SPC4A-I (WT) or its propep-
tide cleavage site mutants (RQ149 and KR144) were biosynthetically
labeled with [35S]Met/Cys for 6 h. Cell extracts (lanes c) or media
(lanes m) were immunoprecipitated with anti-SPC4 antiserum, fol-
lowed by resolution by SDS-PAGE.
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HEK293 cells (Fig. 3A), the SPC4 maturation was almost
blocked and an accumulation of 110-kDa proSPC4 proteins
was observed in the cells, although in an overexposed auto-
radiogram small amounts of mature proteins were also ob-
served in the media with both mutants (data not shown).
To examine whether SPC4 itself might activate the proSPC4
in an intermolecular manner, co-transfection of the process-
ing-defective SPC4 mutant and an active SPC4 were per-
formed. To this aim, a catalytically active mutant
SPC4v680, lacking the entire C-terminal cysteine-rich region,
was constructed, to enable two simultaneously expressed
SPC4 proteins to be distinguished based on their molecular
weights. The integrity of the truncated SPC4 in cleaving sub-
strate molecules was con¢rmed by co-expression study with
mutant prorenin M2Rÿ6Rÿ4 [15] (data not shown). Despite
the simultaneous expression of catalytically active SPC4v680,
the biosynthetic processing of neither the wild-type nor active
site mutant SA420 was stimulated (Fig. 3B). These results
indicate that SPC4 maturation involves intramolecular auto-
catalytic removal of the propeptide, whereas other proteases
may contribute to this process to only a small extent.
3.4. Oligomeric structure of SPC4
Until now, the oligomeric state of SPC family proteases has
not been thoroughly characterized. We therefore used sucrose
density gradient velocity centrifugation of metabolically radio-
labeled cells transiently expressing SPC4A to determine rela-
tive complex size (Fig. 4A). When a lysate of COS-1 cells
expressing SPC4A-I was analyzed, the mature protein both
in the cell extract and culture medium sedimented at a size
compatible with it being a monomer. In contrast, the precur-
sor form of SPC4 in the cells migrated not only as a mono-
meric form but also as larger complexes, including a dimer-
sized complex. A more accurate estimation of the size of SPC4
was obtained by chemical cross-linking with dimethyl suber-
imidate (DMS) followed by immunoblotting (Fig. 4B). When
lysates of transfected cells were analyzed, substantial fractions
of both the wild-type and the active site mutant SA420 which
accumulates in the cells as a precursor were cross-linked into a
dimer-sized V230-kDa species. On the other hand, mature
SPC4 secreted into the culture medium was not cross-linked
under the same conditions. The fact that the complex size
observed in the cells ¢ts a SPC4 dimer suggests the existence
of such an oligomeric structure, although we can not exclude
the possibility that some other cellular protein of a similar size
associates with proSPC4. These ¢ndings demonstrate that the
precursor of SPC4 assembles into a larger complex, probably
a dimer, in the ER whereas the proteolytically processed ma-
ture SPC4 exists in a monomeric form. This suggests that the
propeptide cleavage of SPC4 in the ER a¡ects its tertiary or
quaternary structure.
4. Discussion
The biosynthetic processing and intracellular transport of
SPCs are thought to provide these enzymes with opportunities
for regulating the e⁄ciency of substrate processing. For in-
stance, SPC1 (furin), SPC6B (PC6B) and SPC7 (LPC/PC8)
localize to the trans-Golgi network (TGN) through their hy-
drophobic transmembrane regions, and thus can process pre-
cursor proteins that pass through this compartment. On the
other hand, SPC2 (PC2), SPC3 (PC3) and SPC6A (PC6A) are
known to be sorted into the secretory granules of endocrine or
neuroendocrine cells and process precursor proteins there
[3,18]. Thus, the proprotein processing by SPCs can be con-
trolled through the compartmentalization of both the enzymes
and substrates. SPC4A (PACE4A) is expressed in both the
regulated and non-regulated cells and does not have any
membrane anchoring sequence, suggesting that SPC4A is se-
creted to the extracellular space mainly through the constitu-
tive secretory pathway. In this case, the enzyme would only
temporarily access substrates during the intracellular trans-
port, or it would play a role in the extracellular milieu after
its secretion. In either case, the availability of the active en-
zyme for substrate processing is limited by the propeptide
cleavage in the ER. Since the maturation of SPC4 seems to
be extremely slow and ine⁄cient ([14] and our unpublished
results), this step seems to play a rate-determining role for
both the generation and release of the active enzyme.
Concerning SPC1, SPC3 and SPC7, the processing of the
precursor proteins is known to occur via an autocatalytic
intramolecular mechanism in the ER [19^24]. A recent study
with SPC1 (furin) showed that the initial propeptide cleavage
in the ER is not su⁄cient for the activation of SPC1 and a
second cleavage within the propeptide occurring in the TGN
is required to dissociate the propeptide from the rest of the
molecule for full activation [25]. In the case of SPC3 (PC1/
PC3), not only propeptide cleavage, but also C-terminal cleav-
age in the secretory granules is required for maximal activa-
tion [26^29]. The activation of SPC2 (PC2) is rather unique
among the SPCs: it occurs slowly after the exit of SPC2 from
the ER by an intermolecular autocatalytic mechanism and
chaperonin-like protein 7B2 is involved in this process
[23,30^34]. Thus the SPC activation does not appear to be a
simple event, and besides the common mechanism, each SPC
may have its own activation mechanism to achieve strict reg-
ulation of its activities. The current study demonstrates that
proSPC4 processing occurs largely through an autocatalytic
unimolecular reaction in the ER and is prerequisite to its
export from this compartment. However, some processing still
occurs even when the active site residues of SPC4 are mutated
(Fig. 3A), indicating the partial involvement of another mech-
anism in this process. Both the autoactivation and activation
by other proteases in trans may be needed for maximum e⁄-
ciency of SPC4 maturation. Recently, Mains et al. reported
accelerated maturation of rat SPC4 on truncation of its C-
terminal cysteine-rich region [14]; however, this was not ob-
served for human SPC4 (data not shown). Some di¡erences in
activation may exist between human and rat SPC4.
Many bioactive proteins are primarily synthesized as pro-
proteins with N-terminal propeptides. Several functions of
propeptides have been described, such as stabilization or se-
cretion of active proteins, multimer assembly, sorting to sub-
cellular organelles, inhibition of enzymatic activities, and
guiding of correct protein folding. In most SPCs, the cleavage
of the N-terminal propeptide occurs in the ER and is required
for the export of the protein from the compartment. However,
the underlying mechanism for the acquisition of the export
competence remains to be established. A possible explanation
is that the propeptide of the SPCs harbors a speci¢c signal for
retention in the ER. Alternatively, export of SPCs from the
ER could be mediated by a change in the physical-chemical
properties of the protein which is induced by the propeptide
cleavage. Our observations that some proSPC4 in the cells
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exists as larger complexes whereas the mature protein is only
in a monomeric form suggest some relationship between the
propeptide cleavage in the ER and tertiary or quaternary
structure of the protein. Co-expression studies of SPC4A
with mutant prorenin M2Rÿ6Rÿ4 in the presence of BFA
indicate that SPC4 is catalytically inactive against substrate
proproteins in trans in the ER even though its propeptide has
been cleaved (data not shown). Thus, the conformational
change and subsequent export from the ER induced by the
propeptide cleavage may be important for the regulation of
the e⁄ciency of substrate processing by SPC4. In addition, the
oligomeric complex of proSPC4 formed in the ER may have
some implications for the mechanism of self-cleavage of its
propeptide. Although it is not clear if the same is applicable
to other members of the SPC family, the precise relationship
between this oligomeric structure and the export of the pro-
tein from the ER is of considerable interest.
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